Who is sponsoring NCT02424461?

NCT02424461 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT02424461?

Interventions in NCT02424461: Ceftriaxone, Ofloxacine, Ofloxacine, Placebo of ofloxacine.

What condition does NCT02424461 study?

NCT02424461 studies Acute Male Urinary Tract Infection.

Is NCT02424461 still recruiting?

NCT02424461 is currently completed. Last updated 1 May 2024.

Last reviewed 2024-05-01 · How we verify

NCT02424461: PROSTASHORT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection

Completed Phase 3 Last updated 1 May 2024

What this trial tests

Phase 3 trial testing Ceftriaxone in Acute Male Urinary Tract Infection in 274 participants. Completed in 25 July 2019.

Timeline

25 January 2015

Primary endpoint
25 February 2019

25 July 2019

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	274
Start date	25 January 2015
Primary completion	25 February 2019
Estimated completion	25 July 2019
Sites	1 location across France

Drugs / interventions tested

Ceftriaxone (ceftriaxone) — full drug profile →
Ofloxacine — full drug profile →
Ofloxacine — full drug profile →
Placebo of ofloxacine — full drug profile →

Conditions studied

Acute Male Urinary Tract Infection — all drugs for Acute Male Urinary Tract Infection →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, male only, with Acute Male Urinary Tract Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate the treatment of urinary tract infection (UTI) in men. The investigators are looking to see if shorter duration of antibiotics (7 days) is not inferior to a longer duration of antibiotics (14 days). The investigators will also study whether longer treatment leads to an increase in antibiotic resistant bacteria in the gut microbiota or an increase in drug side effects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Lafaurie M, Chevret S, Fontaine JP, Mongiat-Artus P, et al · · 2023 · cited 22× · PMID 36785526 · DOI 10.1093/cid/ciad070

Verify or expand the search:

Other trials of Ceftriaxone

Trials testing the same drug.

NCT05980871 — Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline · Phase 4 · terminated
NCT05470517 — Antibiotic Instillation in Appendicitis · Phase 2 · completed
NCT05294588 — Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae · Phase 2 · completed
NCT05149287 — PROPER Trial of Pain and Inflammation After Knee Arthroscopy · Phase 2 · terminated
NCT05079620 — Early Antibiotics After Aspiration in ICU Patients · Phase 4 · terminated

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02424461 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 1 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02424461.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing